Does Medicare cover Ozempic?

Medicare Part D covers Wegovy and Zepbound for weight loss starting July 1, 2026. Ozempic is only covered when prescribed for type 2 diabetes, not weight loss.

Which states cover GLP-1 on Medicaid?

Coverage varies by state. As of June 2026, about 5 states cover GLP-1 medications for weight loss through Medicaid, 23 cover them with prior authorization or for diabetes only, and 23 do not cover weight-loss GLP-1s.

How do I get prior authorization for Wegovy?

Your prescribing doctor submits a prior authorization request to your insurance plan, typically including your BMI, previous weight loss attempts, and any weight-related health conditions.

What if my insurance denies GLP-1 coverage?

You can appeal the denial through your insurance company's appeals process. Ask your doctor to write a letter of medical necessity explaining why GLP-1 treatment is appropriate for you.

Does Insurance Cover GLP-1 Medication?

Short answer: Medicare Part D begins covering Wegovy and Zepbound for eligible beneficiaries July 1, 2026 through the GLP-1 Bridge ($50/mo flat copay; eligible Part D enrollees get access automatically, no plan opt-in). Medicaid covers GLP-1 for obesity in only about 5 states; most others limit coverage to Type 2 diabetes or require prior authorization. Major private plans (BCBS, Aetna, UHC, Cigna, Humana, Kaiser) cover GLP-1 with prior auth and BMI/comorbidity criteria.

Last updated: June 2026

Medicare GLP-1 Bridge Medicaid by state Private carriers Prior authorization

Couple reviewing health insurance coverage options together

Skip the coverage research

Answer 5 questions and we'll match you with a provider that handles the insurance paperwork, or routes you to the cheapest cash-pay option if coverage isn't realistic. Takes 90 seconds.

Take the 90-second quiz

Free alert

Medicare GLP-1 Bridge opens July 1, 2026

We'll email when the $50/mo Bridge accepts enrollment and what proof of eligibility looks like.

Medicare GLP-1 Bridge / Demonstration Pathway

The Medicare GLP-1 Bridge is a nationwide CMS demonstration that runs July 1, 2026 through December 31, 2027. Eligible Medicare Part D enrollees gain access automatically; Part D plans do not have to opt in. The $50 monthly copay is flat and does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap. See the full Medicare GLP-1 Bridge guide.

July 1, 2026 to Dec 31, 2027

A nationwide CMS demonstration, separate from the Part D benefit. Eligible Part D enrollees gain access automatically; plans do not opt in.

$50 / Month Flat Copay

A flat $50 copay that does not rise with your dose, and does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap.

Wegovy, Zepbound KwikPen, Foundayo

Covers all formulations of Wegovy and Foundayo, plus the Zepbound KwikPen. Compounded GLP-1s are not covered.

Three CMS eligibility paths

BMI 35+, or BMI 30+ with heart failure, uncontrolled hypertension, or CKD, or BMI 27+ with pre-diabetes, prior heart attack, prior stroke, or symptomatic PAD.

How to Get Medicare Part D Coverage

Confirm you have Part D coverage

Check your Medicare card or call 1-800-MEDICARE to verify your Part D enrollment. Medicare Advantage plans with drug coverage (MA-PD) also qualify.

Ask your doctor about anti-obesity medication

Schedule an appointment with your primary care provider or a weight management specialist. They will evaluate whether a GLP-1 medication is appropriate based on your BMI and health history.

Your doctor contacts your Part D plan for coverage

Your prescribing physician submits the prescription and any required prior authorization to your Part D plan. Once approved, you can fill your prescription at a participating pharmacy.

State-by-State Medicaid Coverage

Medicaid coverage for GLP-1 weight loss medications varies significantly by state. Some states cover these medications for obesity treatment, while others limit coverage to Type 2 diabetes only. Use the filters below to find your state. See national Medicaid GLP-1 coverage by state.

Find your state

Showing 51 of 51 states & territories

Medicaid GLP-1 coverage status by state. Select a row to view detailed coverage notes.
State	Status	Notes
	Not Covered	Alabama Medicaid does not cover GLP-1 medications for obesity; coverage is limited to Type 2 diabetes management with strict criteria.
	Prior Authorization Required	Denali KidCare and Alaska Medicaid cover GLP-1 drugs for Type 2 diabetes with prior authorization, but obesity coverage remains limited.
	Prior Authorization Required	Covers GLP-1 agonists for Type 2 diabetes with prior authorization; weight-loss-only medications such as Wegovy, Zepbound, and Saxenda are not on the AHCCCS formulary and are not covered.
	Not Covered	Arkansas Medicaid covers GLP-1 medications only for Type 2 diabetes management and does not provide coverage for obesity treatment.
	Not Covered	Medi-Cal removed anti-obesity GLP-1 drugs (Wegovy, Zepbound, Saxenda) from its Contract Drugs List effective January 1, 2026; GLP-1s are no longer covered for weight loss for members 21 and older. They remain covered for Type 2 diabetes. Limited exceptions apply, including members under 21 through EPSDT and specific non-obesity uses such as cardiovascular disease or obstructive sleep apnea.
	Not Covered	Health First Colorado (Colorado Medicaid) covers GLP-1 agonists for Type 2 diabetes but does not cover them for weight loss or obesity. Anti-obesity agents such as Saxenda, Qsymia, Contrave, and Xenical are not a covered benefit (Appendix P, effective 10/01/2025). Where medically indicated, coverage may apply for non-obesity uses such as cardiovascular risk reduction or obstructive sleep apnea.
	Not Covered	Connecticut Medicaid (HUSKY Health) covers GLP-1 medications for Type 2 diabetes, Wegovy for cardiovascular indications, and Zepbound for sleep apnea, but does not cover GLP-1s for weight loss. The state's 2023 obesity-coverage mandate was implemented in July 2025 with non-GLP-1 medications only (orlistat, Xenical, phentermine).
	Prior Authorization Required	Delaware Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage requires documentation of comorbidities.
	Not Covered	DC Medicaid covers GLP-1 agonists for Type 2 diabetes but does not cover them for weight loss or obesity. Verified against the DC Medicaid Preferred Drug List effective March 23, 2026.
	Not Covered	Florida Medicaid (Statewide Medicaid Managed Care) does not cover GLP-1 drugs for weight loss; coverage is restricted to Type 2 diabetes with prior authorization.
	Not Covered	Georgia Medicaid covers GLP-1 agonists only for Type 2 diabetes management; the state has not expanded coverage to obesity treatment indications.
	Not Covered	Hawaii Med-QUEST covers GLP-1 medications for Type 2 diabetes but does not cover them for weight loss. Hawaii Medicaid currently excludes weight-loss GLP-1s; 2026 legislation to require coverage (SB 3195) died in committee.
	Not Covered	Idaho Medicaid covers GLP-1 drugs for Type 2 diabetes only and does not currently extend coverage to obesity or weight management indications.
	Not Covered	Illinois Medicaid covers GLP-1 medications only with a Type 2 diabetes diagnosis (Victoza, Ozempic, Mounjaro, Rybelsus). Wegovy, Zepbound, and Saxenda are not covered for weight loss; Illinois Medicaid regulation excludes anorectic (weight-loss) drugs.
	Prior Authorization Required	Indiana Medicaid (Healthy Indiana Plan) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited and requires physician documentation.
	Prior Authorization Required	Iowa Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; weight management coverage is under ongoing review by the Iowa Department of Health and Human Services.
	Not Covered	KanCare (Kansas Medicaid) limits GLP-1 coverage to Type 2 diabetes management and does not include obesity as a covered indication.
	Prior Authorization Required	Kentucky Medicaid (Medicaid Managed Care) covers GLP-1 medications for diabetes with prior authorization; obesity coverage eligibility varies by managed care organization.
	Prior Authorization Required	Louisiana Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization and is evaluating expanded coverage for obesity treatment given the state's high obesity rates.
	Not Covered	MaineCare covers GLP-1 medications for Type 2 diabetes but does not cover them for weight loss. Legislation to require obesity coverage (LD 480) died in committee in 2025.
	Not Covered	Maryland Medicaid does not cover GLP-1 medications for weight loss alone. It covers bariatric surgery and intensive behavioral therapy for obesity, and covers GLP-1s only with a qualifying condition (Type 2 diabetes; Wegovy for cardiovascular disease or MASH; Zepbound for obstructive sleep apnea). Senate Bill 496, introduced in the 2026 session, would expand coverage to anti-obesity medications, proposed for January 2027.
	Covered	MassHealth covers GLP-1 agonists for weight loss with prior authorization through June 30, 2026. Effective July 1, 2026, MassHealth no longer covers Saxenda, Wegovy, or Zepbound when used for weight loss; coverage continues only for other medically accepted indications such as Type 2 diabetes and cardiovascular risk. Prior authorizations approved for obesity without a documented comorbidity expire June 30, 2026.
	Prior Authorization Required	Michigan Medicaid (Healthy Michigan Plan) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available for members meeting specific BMI and comorbidity criteria.
	Covered	Minnesota Medical Assistance covers GLP-1 agonists for diabetes and has approved obesity treatment coverage with prior authorization for eligible enrollees.
	Not Covered	Mississippi Medicaid covers GLP-1 medications only for Type 2 diabetes; the state has not expanded Medicaid and does not cover these drugs for obesity treatment.
	Prior Authorization Required	Missouri HealthNet covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage was not included following the state's 2021 Medicaid expansion.
	Prior Authorization Required	Montana Medicaid (Healthy Montana Kids Plus) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited under the current benefit structure.
	Prior Authorization Required	Nebraska Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity-specific coverage is not currently included in the Nebraska Heritage Health benefit package.
	Prior Authorization Required	Nevada Medicaid covers GLP-1 agonists for diabetes with prior authorization and is actively reviewing expanded obesity coverage following the state's full Medicaid expansion.
	Prior Authorization Required	NH Medicaid (Granite Advantage Health Care Program) covers GLP-1 medications for diabetes with prior authorization; obesity treatment coverage requires meeting clinical criteria.
	Not Covered	NJ FamilyCare does not cover GLP-1 medications solely for obesity. They are covered for other FDA-approved indications, including Type 2 diabetes, Wegovy for cardiovascular risk, and Zepbound for obstructive sleep apnea.
	Covered	New Mexico Medicaid (Centennial Care/Turquoise Care) covers Saxenda, Wegovy, and Zepbound for obesity with prior authorization. Criteria include a BMI of 40 or higher (or 35 or higher with a weight-related condition such as hypertension, diabetes, or dyslipidemia); authorization is granted for an initial three-month period.
	Not Covered	New York Medicaid (NYRx) covers GLP-1 agonists for Type 2 diabetes and covers Wegovy with prior authorization for cardiovascular risk reduction, but state regulation excludes drugs prescribed for weight loss. Legislation to require obesity coverage (A9360) is pending.
	Covered	NC Medicaid covers GLP-1 agonists for Type 2 diabetes and, following reinstatement of anti-obesity coverage in late 2025, for obesity treatment with prior authorization and clinical criteria.
	Prior Authorization Required	North Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not part of the current ND Medicaid benefit structure.
	Prior Authorization Required	Ohio Medicaid covers GLP-1 medications for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans with clinical documentation.
	Prior Authorization Required	SoonerCare (Oklahoma Medicaid) covers GLP-1 agonists for diabetes with prior authorization following the state's 2021 Medicaid expansion; obesity coverage is limited.
	Not Covered	The Oregon Health Plan does not cover GLP-1 medications for weight loss in adults. GLP-1s are covered with prior authorization for Type 2 diabetes, for cardiovascular risk reduction (Wegovy), and for obstructive sleep apnea (Zepbound), with a limited pathway for adolescents ages 12 to 20 who have severe obesity.
	Prior Authorization Required	Pennsylvania Medicaid (MA Program) covers GLP-1 agonists for diabetes with prior authorization; obesity treatment coverage eligibility depends on the managed care organization.
	Covered	Rhode Island Medicaid (Medicaid) covers GLP-1 medications for diabetes and obesity with prior authorization, reflecting the state's comprehensive Medicaid expansion benefit package.
	Not Covered	South Carolina Healthy Connections (Medicaid) covers GLP-1 drugs for Type 2 diabetes only and does not include obesity as a covered treatment indication.
	Prior Authorization Required	South Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not currently part of the state's Medicaid formulary.
	Prior Authorization Required	TennCare expanded coverage to include FDA-approved obesity medications, including GLP-1s such as Wegovy and Zepbound, effective August 1, 2025 for members ages 21 and older. Weight-loss obesity coverage is available with prior authorization and quantity limits, and the interim PA criteria were updated January 1, 2026.
	Not Covered	Texas Medicaid does not cover GLP-1 drugs for obesity; coverage is restricted to Type 2 diabetes with prior authorization, and the state has not expanded Medicaid.
	Prior Authorization Required	Utah Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage is limited under the state's partial Medicaid expansion (Utah Medicaid Expansion).
	Not Covered	Vermont Medicaid excludes drugs used for weight loss from its pharmacy benefit. GLP-1s are covered for Type 2 diabetes, and Wegovy only for cardiovascular event reduction, not for obesity treatment.
	Prior Authorization Required	Virginia Medicaid (Cardinal Care) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans following the 2019 Medicaid expansion.
	Not Covered	Apple Health (Washington Medicaid) covers GLP-1 medications for Type 2 diabetes and for specific non-obesity indications such as cardiovascular event reduction (MACE), MASH, and obstructive sleep apnea, but does not cover them for weight loss alone.
	Prior Authorization Required	West Virginia Medicaid covers GLP-1 medications for diabetes with prior authorization; obesity coverage is under review given the state's high rates of obesity and diabetes.
	Prior Authorization Required	BadgerCare Plus (Wisconsin Medicaid) covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage is not included in the current benefit structure.
	Not Covered	Wyoming Medicaid covers GLP-1 drugs for Type 2 diabetes management only; the state has not expanded Medicaid and does not cover these medications for obesity treatment.

State-Level Coverage Guides

Detailed GLP-1 insurance coverage breakdowns for each state, including Medicaid rules, private carrier stances, and local provider availability. Or skip the coverage research and find GLP-1 providers near you across all 9,700+ clinics in our directory.

GLP-1 Coverage by Payer

Coverage guides for major insurers and public programs, including prior authorization rules, formulary tiers, and savings options.

Aetna UnitedHealthcare Cigna Blue Cross Blue Shield Humana Kaiser Permanente Medicare GLP-1 Bridge Medicaid by State

Private Insurance Coverage

Most major private insurance carriers cover GLP-1 medications for Type 2 diabetes, and an increasing number now cover weight loss indications. Coverage varies by plan and employer, so check with your specific carrier for details.

Aetna

Aetna covers GLP-1 medications for Type 2 diabetes on most plans. Weight loss coverage varies by employer-sponsored plan and typically requires prior authorization with documented BMI criteria.